Although they have demonstrated some benefit as immunotherapy agents against cancer, AIDS and CFS/ME, TLR3 agonists also cause adverse effects in some individuals and have not yet been authorised for use in vaccines. The gene discussed is TLR3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.